Biocon, Mylan Challenge Roche Suit Against Herceptin Generic Versions
This article was originally published in PharmAsia News
Executive Summary
Biocon and Mylan, in a joint filing with the Delhi High Court, have challenged a requested ban on their sales of generic versions of Roche's Herceptin (trastuzumab) for treating breast cancer.